Cargando…
Potential blood-based markers of celiac disease
BACKGROUND: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD). Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active CD, several other scenarios involve a need for additional blood-based C...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287385/ https://www.ncbi.nlm.nih.gov/pubmed/25298177 http://dx.doi.org/10.1186/1471-230X-14-176 |
_version_ | 1782351779780886528 |
---|---|
author | Bragde, Hanna Jansson, Ulf Fredrikson, Mats Grodzinsky, Ewa Söderman, Jan |
author_facet | Bragde, Hanna Jansson, Ulf Fredrikson, Mats Grodzinsky, Ewa Söderman, Jan |
author_sort | Bragde, Hanna |
collection | PubMed |
description | BACKGROUND: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD). Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active CD, several other scenarios involve a need for additional blood-based CD markers. METHODS: We investigated the levels of messenger RNA (mRNA) in whole blood (n = 49) and protein in plasma (n = 22) from cases with active CD (n = 20), with confirmed CD and normalized histology (n = 15), and without a CD diagnosis (n = 14). Group differences were analyzed using Kruskal-Wallis one-way analysis of variance by ranks. We also investigated correlations between levels of potential markers, histopathology according to the modified Marsh scale, and CD risk gradient based on HLA type, using Spearman rank correlation. The relation between HLA-DQ2 gene dose effect and the expression levels of selected blood-based markers was investigated using the Mann–Whitney U test. Finally, the diagnostic performance of anti-TG2, potential blood-based CD markers, and logistic regression models of combined markers was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: CXCL11 protein levels and TNFRSF9 and TNFSF13B mRNA levels were identified as potential CD markers. These are all affected by or involved in the regulation of the NF-κB complex. CXCL11 protein levels and IL21 and IL15 mRNA levels were correlated with histopathology according to the modified Marsh scale, as were the established CD markers. HLA genotype risk and HLA-DQ2 gene dose effect did not show any significant relations with either the potential CD markers or the established CD markers. ROC curve analysis revealed a slight, non-significant increase in the area under the curve for the combined use of anti-TG2 and different constellations of potential blood-based CD markers compared to anti-TG2 alone. CONCLUSIONS: The CD markers identified in this study further emphasize the significance of components related to NF-κB regulation in relation to CD. However, the relevance of CXCL11, TNFSF13B, TNFRSF9, and other NF-κB interacting proteins recognized by pathway analysis, needs to be further investigated in relation to diagnosis and monitoring of CD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-230X-14-176) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4287385 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-42873852015-01-09 Potential blood-based markers of celiac disease Bragde, Hanna Jansson, Ulf Fredrikson, Mats Grodzinsky, Ewa Söderman, Jan BMC Gastroenterol Research Article BACKGROUND: Blood-based diagnostics has the potential to simplify the process of diagnosing celiac disease (CD). Although high levels of autoantibodies against tissue transglutaminase (anti-TG2) are strongly indicative of active CD, several other scenarios involve a need for additional blood-based CD markers. METHODS: We investigated the levels of messenger RNA (mRNA) in whole blood (n = 49) and protein in plasma (n = 22) from cases with active CD (n = 20), with confirmed CD and normalized histology (n = 15), and without a CD diagnosis (n = 14). Group differences were analyzed using Kruskal-Wallis one-way analysis of variance by ranks. We also investigated correlations between levels of potential markers, histopathology according to the modified Marsh scale, and CD risk gradient based on HLA type, using Spearman rank correlation. The relation between HLA-DQ2 gene dose effect and the expression levels of selected blood-based markers was investigated using the Mann–Whitney U test. Finally, the diagnostic performance of anti-TG2, potential blood-based CD markers, and logistic regression models of combined markers was evaluated using receiver operating characteristic (ROC) curve analysis. RESULTS: CXCL11 protein levels and TNFRSF9 and TNFSF13B mRNA levels were identified as potential CD markers. These are all affected by or involved in the regulation of the NF-κB complex. CXCL11 protein levels and IL21 and IL15 mRNA levels were correlated with histopathology according to the modified Marsh scale, as were the established CD markers. HLA genotype risk and HLA-DQ2 gene dose effect did not show any significant relations with either the potential CD markers or the established CD markers. ROC curve analysis revealed a slight, non-significant increase in the area under the curve for the combined use of anti-TG2 and different constellations of potential blood-based CD markers compared to anti-TG2 alone. CONCLUSIONS: The CD markers identified in this study further emphasize the significance of components related to NF-κB regulation in relation to CD. However, the relevance of CXCL11, TNFSF13B, TNFRSF9, and other NF-κB interacting proteins recognized by pathway analysis, needs to be further investigated in relation to diagnosis and monitoring of CD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-230X-14-176) contains supplementary material, which is available to authorized users. BioMed Central 2014-10-09 /pmc/articles/PMC4287385/ /pubmed/25298177 http://dx.doi.org/10.1186/1471-230X-14-176 Text en © Bragde et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Bragde, Hanna Jansson, Ulf Fredrikson, Mats Grodzinsky, Ewa Söderman, Jan Potential blood-based markers of celiac disease |
title | Potential blood-based markers of celiac disease |
title_full | Potential blood-based markers of celiac disease |
title_fullStr | Potential blood-based markers of celiac disease |
title_full_unstemmed | Potential blood-based markers of celiac disease |
title_short | Potential blood-based markers of celiac disease |
title_sort | potential blood-based markers of celiac disease |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287385/ https://www.ncbi.nlm.nih.gov/pubmed/25298177 http://dx.doi.org/10.1186/1471-230X-14-176 |
work_keys_str_mv | AT bragdehanna potentialbloodbasedmarkersofceliacdisease AT janssonulf potentialbloodbasedmarkersofceliacdisease AT fredriksonmats potentialbloodbasedmarkersofceliacdisease AT grodzinskyewa potentialbloodbasedmarkersofceliacdisease AT sodermanjan potentialbloodbasedmarkersofceliacdisease |